Oni Julius K, Pinero Joseph R, Saltzman Bryan M, Jaffe Fredrick F
1 Department of Orthopaedic Surgery, Einstein Medical Center, Philadelphia - USA.
Hip Int. 2014 May-Jun;24(3):256-62. doi: 10.5301/hipint.5000109. Epub 2014 Jan 28.
Heterotopic ossification (HO) is a well-known complication of total hip arthroplasty (THA), especially when the direct lateral approach is used. In this study, we examined the effect of the selective COX-2 inhibitor, celecoxib, on the rates of HO after THA. A control group consisting of 108 patients that did not receive celecoxib was compared with a study group consisting of 106 patients that did receive celecoxib. We assessed the presence and grade of HO using the Brooker classification and Harris hip scores were determined pre- and postoperatively to better quantify clinical outcomes. In this retrospective study of prospectively collected data, celecoxib is associated with a significant reduction in the incidence of HO in patients undergoing THA.
异位骨化（HO）是全髋关节置换术（THA）一种众所周知的并发症，尤其是在采用直接外侧入路时。在本研究中，我们研究了选择性环氧化酶-2（COX-2）抑制剂塞来昔布对THA后HO发生率的影响。将由108例未接受塞来昔布治疗的患者组成的对照组与由106例接受塞来昔布治疗的患者组成的研究组进行比较。我们使用布鲁克（Brooker）分类法评估HO的存在情况和分级，并在术前和术后测定Harris髋关节评分，以更好地量化临床结果。在这项对前瞻性收集数据的回顾性研究中，塞来昔布与接受THA患者的HO发生率显著降低相关。
